Adverse events during the titration phase of interferon-beta in remitting-relapsing multiple sclerosis are not predicted by body mass index nor by pharmacodynamic biomarkers

Muñoz, Delicias; Escartín, Antonio; Dapena, D; Coret, Francisco; Fernández-Uría, Dionisio; Pérez, Domingo; Casanova, Bonaventura; Guijarro-Castro, Cristina; Munteis, Elvira; Amigo, María del-Campo; Pego, Robustiano; Calles, Carmen; Garcı́a-Rey, César; Monsalve, Nuria; Sánchez-Matienzo, David

doi:10.1186/1471-2377-13-82

Cited by 3 publications

(3 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Namely, a significant number of patients had been treated with interferon beta-1b (34 %), whose one of the possible adverse effects is a reduction of BW. 12,46 The results obtained in the present study can be explained by the fact that MS patients were under a constant medical supervision, in touch with their therapists who gave them advice on proper diet, need for physical activity and other measures of hygienic and dietetic regimens, which led to the levelling of body weight, as opposed to healthy the individuals in the control group.…”

Section: Resultsmentioning

confidence: 74%

Association of body mass index with progression and prediction of multiple sclerosis

Tadić¹,

Đajić²,

Grgić³

et al. 2020

Scripta Medica

View full text Add to dashboard Cite

Background/Aim: Multiple sclerosis is a disease whose aetiology involves multifactorial interactions among genetic and environmental factors. Obesity is one of the most important environmental factors conducive to the onset and progression of the disease. The aim of the study was to determine the value of body mass index (BMI) in a population of patients with multiple sclerosis compared to the general population, in order to assess the relation between the BMI and physical disability in patients with multiple sclerosis and the influence of the BMI on the course and progression of the disease. Methods: A cross-sectional study was performed in 100 patients suffering from multiple sclerosis (experimental group) and 50 healthy people (control group). In order to determine the degree of physical disability, the Expanded Disability Status Scale (EDSS) was used. Clinical and demographic data and values of the BMI in both studied groups were collected. Statistical analysis included the descriptive statistics, t-test, chi-square test, analysis of variance, correlation and regression analysis. Results: Mean body weight and BMI were significantly higher in the control group (p< 0.05). There was no significant correlation between EDSS and BMI (p = 0.574). There was a correlation between the course of MS and the fact whether BMI was abnormal or normal (p = 0.031). Conclusion: BMI is an environmental factor that significantly correlates with the progression and prediction of multiple sclerosis, but not to the degree of physical disability.

show abstract

Section: Resultsmentioning

confidence: 74%

Association of body mass index with progression and prediction of multiple sclerosis

Tadić¹,

Đajić²,

Grgić³

et al. 2020

Scripta Medica

View full text Add to dashboard Cite

show abstract

“…Thus, regulatory responses induced by cargo DNA sensing by cytosolic DNA sensors or by CDNs to activate the STING/IFN‐β pathway can be exploited to attenuate clinically relevant autoimmune syndromes. Recombinant IFN‐β is a standard treatment for MS, although its mode of action is poorly defined and the recurrent interventions required to control MS induce increasingly severe side effects such as severe local pain, headaches, and symptoms comparable with those induced by influenza infections , leading to therapy cessation in many cases. Moreover, another FDA‐approved anti‐MS drug, glatiramer acetate (Copaxone), has been shown to stimulate IDO‐dependent regulatory responses that ameliorate EAE .…”

Section: Therapeutic Implications: Using Dna To Modulate Autoimmunitymentioning

confidence: 99%

Cytosolic DNA sensing via the stimulator of interferon genes adaptor: Yin and Yang of immune responses to DNA

et al. 2014

View full text Add to dashboard Cite

Summary DNA is immunogenic and many cells express cytosolic DNA sensors that activate the Stimulator of Interferon Genes (STING) adaptor to trigger interferon type I (IFN-β) release, a potent immune activator. DNA sensing to induce IFN-β triggers host immunity to pathogens but constitutive DNA sensing can induce sustained IFN-β release which incites autoimmunity. Here we focus on cytosolic DNA sensing via the STING/IFN-β pathway which regulates immune responses. Recent studies reveal that cytosolic DNA sensing via the STING/IFN-β pathway induces indoleamine 2,3 dioxygenase (IDO), which catabolizes tryptophan to suppress effector and helper T-cell responses and activate Foxp3-lineage CD4+ regulatory T (Treg) cells. During homeostasis, and in some inflammatory settings, specialized innate immune cells in the spleen and lymph nodes may ingest and sense cytosolic DNA to reinforce tolerance that prevents autoimmunity. However, malignancies and pathogens may exploit DNA-induced regulatory responses to suppress natural and vaccine-induced immunity to malignant and infected cells. In this review we discuss the biologic significance of regulatory responses to DNA and novel approaches to exploit DNA-induced responses immune for therapeutic benefit. The ability of DNA to drive tolerogenic or immunogenic responses highlights the need to evaluate immune responses to DNA in physiologic settings relevant to disease progression or therapy.

show abstract

“…The mode of action of IFNβ in responsive MS patients and the reasons for differential responsiveness to IFNβ are not well understood. Moreover, the recurrent IFNβ treatments required to control MS also induce severe progressive toxicities such as severe local pain, headaches, leading to frequent therapy cessation 71 . Speculatively, the toxic effects of IFNβ may arise from lack of local targeting to trigger selective downstream responses to IFN-I by tolerizing cells in spleen.…”

Section: Sting Activators In the Clinic: To Immunize Or To Tolerimentioning

confidence: 99%

STING, nanoparticles, autoimmune disease and cancer: a novel paradigm for immunotherapy?

Lemos¹,

Huang²,

McGaha³

et al. 2014

Expert Review of Clinical Immunology

View full text Add to dashboard Cite

DNA has potent immunogenic properties that are useful to enhance vaccine efficacy. DNA also incites hyper-inflammation and autoimmunity if DNA sensing is not regulated. Paradoxically, DNA regulates immunity and autoimmunity when administered systemically as DNA nanoparticles (DNPs). DNPs regulated immunity via cytosolic DNA sensors that activate the signaling adaptor Stimulator of Interferon Genes (STING). In this review, we describe how DNA sensing to activate STING promotes regulatory responses and discuss the biological and clinical implications of these responses for understanding disease progression and designing better therapies for patients with chronic inflammatory diseases such as autoimmune syndromes or cancer.

show abstract

Adverse events during the titration phase of interferon-beta in remitting-relapsing multiple sclerosis are not predicted by body mass index nor by pharmacodynamic biomarkers

Cited by 3 publications

References 15 publications

Association of body mass index with progression and prediction of multiple sclerosis

Association of body mass index with progression and prediction of multiple sclerosis

Cytosolic DNA sensing via the stimulator of interferon genes adaptor: Yin and Yang of immune responses to DNA

STING, nanoparticles, autoimmune disease and cancer: a novel paradigm for immunotherapy?

Contact Info

Product

Resources

About